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Abstract 
BACKGROUND & AIMS: Wilson disease is a severe disorder of copper metabolism caused 
by mutations in ATP7B, which encodes a copper-transporting ATPase. The disease 
presents with a variable phenotype that complicates the diagnostic process and treatment. 
Little is known about the mechanisms that contribute to the different phenotypes of the 
disease. METHODS: We analyzed 28 variants of ATP7B from patients with Wilson disease 
that affected different functional domains; the gene products were expressed using the 
baculovirus expression system in Sf9 cells. Protein function was analyzed by measuring 
catalytic activity and copper (64Cu) transport into vesicles. We studied intracellular 
localization of variants of ATP7B that had measurable transport activities and were tagged 
with green-fluorescent protein in mammalian cells using confocal laser scanning microscopy. 
RESULTS: Properties of ATP7B variants with pathogenic amino-acid substitution varied 
greatly even if substitutions were in the same functional domain. Some variants had 
complete loss of catalytic and transport activity, whereas others lost transport activity but 
retained phospho-intermediate formation or had partial losses of activity. In mammalian 
cells, transport-competent variants differed in stability and subcellular localization. 
CONCLUSIONS: Variants in ATP7B associated with Wilson disease disrupt the 
protein’s transport activity, result in its mis-localization, and reduce its stability. 
Single assays are insufficient to accurately predict the effects of ATP7B variants the 
function of its product and development of Wilson disease. These findings will 
contribute to our understanding of genotype–phenotype correlation and mechanisms 
of disease pathogenesis. 
KEY WORDS: P-type ATPase; genetic analysis; liver disease; Golgi 
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Wilson disease (WD) is a hereditary disease due to mutations of the copper transporting P-
type ATPase ATP7B. WD is associated with copper accumulation resulting in liver damage 
and/or neurologic symptoms1,2. The manifestations of liver disease vary from clinically 
asymptomatic with only biochemical abnormalities to acute liver failure3. Similarly, the 
spectrum of neurologic manifestations ranges from normal or mild disturbances to a rapid 
and severe progression of neurologic disability4. The mechanisms behind this variability are 
likely to be complex because even monozygotic twins may have different disease 
manifestations5. Genetic studies showed some association between several mutations and 
the age of onset/disease severity6-9; however, robust genotype-phenotype correlation in the 
case of missense mutations has not so far been found, although complete loss of protein 
expression due to non-sense mutations is expected to result in a more severe phenotype. 
This study focuses on one potential source of phenotypic variability – the effect of mutations 
in ATP7B on the function of the corresponding Cu-transporting Wilson ATPase. 
To date, more than 500 different mutations associated with WD are known 
(http://www.wilsondisease.med.ualberta.ca/database.asp)10. The high prevalence of 
compound heterozygosity prevents a clear correlation between genotype and phenotype in 
affected individuals. A large fraction of mutations are missense mutations producing a single 
amino-acid change in Wilson ATPase ATP7B. ATP7B is a large membrane protein located 
in the trans-Golgi network (TGN). In normal liver, ATP7B has two functions: (i) it transports 
copper into the TGN for incorporation into ceruloplasmin and (ii) exports excess copper by 
sequestering metal in vesicles for subsequent biliary excretion. The second function requires 
ATP7B trafficking from TGN to endocytic vesicles in response to elevation of intracellular 
copper concentration. 
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The ATP7B-mediated transport of copper involves several steps. First, ATP7B binds copper 
via its cytosolic N-terminal domain and ATP via the nucleotide-binding domain. ATP is then 
hydrolyzed, and ATP7B becomes transiently phosphorylated at the residue D1027 located in 
the P-domain (catalytic phosphorylation). Subsequent dephosphorylation releases energy 
necessary to transfer copper across membrane (transport step) (Figure 1A,B). Each of these 
steps may be affected by WD-causing mutations11. The effect could be severe resulting in a 
complete loss of ATP7B function, if mutated residues are critical for binding of ATP or 
copper and/or conformational transitions during catalysis. The inactivation of ATP7B could 
also be partial if mutations diminish affinity for substrates, slow down conformational 
transitions or interfere with precise protein targeting to TGN or vesicles. Understanding of 
phenotypic diversity in WD requires knowledge of how causative mutations alter protein 
stability, activity, and localization in the cell. 
Presently, for most of the WD-causing mutations, such detailed information is not available. 
Yeast complementation assay was used to segregate ATP7B mutants into “severe” and 
“mild” categories based on their ability to restore the growth of yeast strain that lacks the 
endogenous copper transporter12-14. Studies in mammalian cells revealed decreased protein 
levels and mislocalization for several mutants15-17 with a surprisingly small effect on copper 
transport, which was evaluated indirectly17. So far, no studies have directly assessed the 
transport or catalytic activity of disease-causing mutants. Such information is necessary for 
future mechanism-based attempts to correct the ATP7B function. Here, we directly 
measured catalytic and transport activity of 28 ATP7B variants representing all protein 
domains (Table 1, Figure 1B) and tested the intracellular localization for mutants, for which 
transport activity was observed. The mutants and variants were chosen based on clinical 
findings (see WD database10) and recent literature; gene variants found in the population 
with no WD symptoms were also characterized. 
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Materials and Methods 
Reagents and cell lines 
All chemicals, unless otherwise specified, were purchased from Sigma (Deisenhofen, 
Germany). Sf9 cells (Invitrogen, Carlsbad, CA) were maintained at 27°C in suspension 
cultures in Sf-900 II (Gibco, Grand Island, NY). HEK293 T-REx™ cells (Invitrogen, Carlsbad, 
CA) were maintained at 37oC in adherent cultures in MEM (Gibco, Carlsbad, CA) media with 
10% FBS, 3% penicillin-streptomycin, 1% non-essential amino acids, 0.1% zeocin, and 0.1% 
blasticidin. 
Generation of Recombinant Baculovirus ATP7B variants 
The plasmid encoding the full-length 4.4-kilobase ATP7B cDNA (pFastBacDual-wt-ATP7B) 
and the catalytically inactive D1027A mutant were previously described18 and used as a 
template. The ATP7B mutations were introduced with the QuikChangeTM site-directed 
mutagenesis kit (Stratagene, La Jolla, CA) and appropriate primers (Supplementary Table 
1). The entire coding sequence of all constructs was verified by automated sequencing. 
Expression in Sf9 insect cells and preparation of membrane fractions 
Maintenance, infection with recombinant viruses, harvesting of Sf9 insect cells, and isolation 
of membrane fractions were carried out as described earlier18,19. To obtain a total 
microsomal fraction, cells from a 50-ml culture were pelleted by centrifugation at 500g (10 
min, 4°C) and then resuspended in 5 ml of homogenizing buffer (HB): 25 mM imidazole, pH 
7.4, 0.25 M sucrose, 1 mM dithiothreitol (DTT), 1 mM 4-(2-Aminoethyl)benzenesulfonyl 
fluoride hydrochloride (AEBSF). One tablet of complete protease inhibitor mixture without 
EDTA (Roche, Basel, Switzerland) was added per 50 ml of buffer solution. Cells were 
homogenized by 20 strokes in a Dounce glass homogenizer, and then centrifuged (10 min, 
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500g). The supernatant was subjected to an additional centrifugation (30 min, 20000g) to 
pellet microsomal membranes, that were then resuspended in HB-buffer and stored at -
80°C. Protein concentration in membrane fraction was determined by the method of Lowry20. 
The expression of wt- and mutant ATP7B was analyzed by separating 50 µg total membrane 
protein on a 7.5% Laemmli gel21 followed by Coomassie staining and Western blotting with 
polyclonal antibody a-ABD (1:20,000)18,19. 
Preparation of vesicles for copper transport 
Sf9 cells were infected with virus encoding wt-ATP7B, empty vector (mock), or ATP7B 
variants and harvested after three days. Cells from a 50 ml culture were pelleted, 
resuspended in 6 ml of ice-cold buffer containing 50 mM Tris, pH 7.0, 50 mM mannitol, 2 mM 
ethylene glycol-bis-(2-aminoethyl)-N,N,N', N'-tetraacetic acid, antipain and leupeptin (each 
diluted 1:1000), phenylmethylsulfonyl fluoride (diluted 1:200), homogenized 20x in a semi-
automatic homogenizer (Schütt homgen plus, Göttingen, Germany) at 3000 rpm, and then 
centrifuged (10 min, 500g, 4°C). Subsequently, the supernatant was centrifuged (1 h, 
100000g) to sediment the membranes. The membranes were resuspended in a sterile 
filtered buffer (SMS): 50 mM sucrose, 100 mM potassium nitrate, 10 mM Hepes/Tris pH 7.4. 
Vesicle formation was facilitated by vortexing and passing several times through a 25-gauge 
5/8-inch needle. The vesicles were stored in liquid nitrogen. Protein concentration was 
determined by the method of Bradford22. To confirm protein expression, all samples were 
analyzed by Western analysis using polyclonal antibody a-ABD18,19. 
64Cu-uptake in vesicles 
The transport assay was performed according to Gmaj et al.23. The vesicle solution was 
thawed, diluted to 5 µg protein/µl with sterile filtered SMS buffer and kept on ice until further 
use. For the transport assay, 20 µl vesicle solution was pre-incubated at 37°C for 1 min. The 
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reaction was started at 37°C by addition of 80 µl sterile filtered radioactive incubation 
solution: 50 mM sucrose, 100 mM KNO3, 10 mM Hepes/Tris pH 7.4, 12.5 mM Mg(NO3)2, 
12.5 mM DTT, 6.25 mM ATP, 2.5 µM CuCl2 (final copper concentration 2 µM), 6 µCi/ml 64Cu 
(Rotop Pharmaka, Radeberg, Germany). For inhibition experiments, orthovanadate was 
added to the incubation solution to a final concentration of 200 µM. The copper transport 
reaction was stopped after 2 min, 5 min, 20 min 45 min, 120 min or 240 min by addition of 
3 ml of ice-cold sterile filtered stopping solution (50 mM sucrose, 100 mM KCl, 10 mM 
Hepes/Tris pH 7.4, 0.5 mM EDTA) and filtered immediately through a 0.45 µm nitrocellulose-
vacuum-filter-system. The filter was washed with 3 ml stopping solution before and after 
filtration and its radioactivity was measured by the γ-Counter Cobra Quantum (PerkinElmer, 
Rodgau-Jügesheim, Germany). To measure the background radioactivity, 3 ml stopping 
solution was added to the vesicle solution on ice prior to the addition of 80 µl incubation 
solution. Vesicles with an empty vector (mock) and inactive variant D1027A were used as 
negative controls. The data were analyzed by a nonlinear regression using SigmaPlot 
software. 
[γ-32P]ATP-phosphorylation 
Membrane preparations (50 µg) containing wt-ATP7B or mutants were resuspended in 
200 µl phosphorylation buffer: 20 mM bis-Tris propane, pH 7, 200 mM KCl, 5 mM MgCl2. 
Radioactive [γ-32P] ATP (5 µCi, specific activity 20 mCi/µmol, PerkinElmer, Waltham, MA) 
was added to a final concentration of 1 µM and the mixture was incubated on ice for 4 min. 
The reaction was stopped by addition of 50 µl of ice-cold 1 mM NaH2PO4 in 50% 
trichloroacetic acid and then centrifuged (10 min, 20000g). The protein pellet was washed 
once with 1 ml ice-cold water and centrifuged a second time for 5 min. The pellet was 
dissolved in 40 µl sample buffer (5 mM Tris-PO4, pH 5.8, 6.7 M urea, 0.4 M DTT, 5% SDS, 
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Bromphenol blue) and 30 µl were loaded on a 7% acidic gel (stacking gel: 5.5% acrylamide, 
41.3 mM TRIS, pH 5.8, 1% SDS, 5% ammonium persulfate, 5% TEMED; separating gel: 7% 
acrylamide, 64.5 mM TRIS, pH 6.8, 1% SDS, 6,25% ammonium persulfate, 6.25% TEMED). 
After electrophoresis the gels were fixed in 10% acetic acid for 10 min and dried on blotting 
paper. The dried gels were exposed overnight either to a screen for the Fuji BAS reader 
(Fuji, Düsseldorf, Germany) or Kodak BioMax MR film (Kodak, Rochester, NY). The photon-
stimulated-luminescence intensity of bands was quantified using Aida Image Analyzer 
(Raytest, Straubenhardt, Germany). To test ATP-dependent dephosphorylation, ATP was 
added after [γ-32P]ATP phosphorylation to a final concentration of 1 mM at room temperature 
and incubated for 10 min before the reaction was stopped and samples were processed in 
the same manner as described above. 
Expression and localization of ATP7B variants in HEK 293 T-REx™ cells 
Selected mutations (L1083F, R969Q, and A874V) were introduced into a GFP-ATP7B 
construct (kindly provided by Dr. Ann Hubbard, Johns Hopkins University) using the 
QuikChange Site Directed Mutagenesis kit and appropriate primers (Supplementary Table 
1). The presence of the desired mutation and the absence of additional mutations were 
confirmed by DNA sequencing. For transfection into mammalian cells, plasmids were 
isolated using a Zyppy™ Endo-free Plasmid Miniprep Kit (Zymo Research, Irvine, CA). HEK 
293 TREx™ cells were seeded on flame-sterilized coverslips in twelve-well plates and 
allowed to grow until approximately 70-80% confluency. Transfections of 2500 ng of plasmid 
DNA were performed in a serum free MEM media for 6 hours using 4 μL of TurboFect™ 
reagent (Fermentas, Glen Burnie, MD) per well. The media was then replaced with Gibco 
MEM media (with 10% FBS, 3% penicillin-streptomycin, 1% non-essential amino acids) and 
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left overnight at 37oC or 28oC. Cells were fixed with chilled 1:1 aceton:methanol mixture for 
30 seconds and blocked overnight in blocking buffer (1% gelatin, 1% BSA in PBS). 
Primary antibody solutions were prepared by diluting into blocking buffer with 0.1% Tween. 
Dilutions were as follows: TGN38 (H-300) Rabbit Polyclonal Antibody (Santa Cruz Biotech, 
Santa Cruz, CA), 1:150; Sheep Antibody to Human TGN46 (GeneTex, Irvine, CA), 1:150; 
Rabbit anti-Calnexin C-terminus (Enzo Life Sciences, Plymouth Meeting, PA), 1:500, 1:250, 
1:150. Sixty µl of each antibody solution was aliquoted on Parafilm within a humidifying 
chamber for each coverslip. Coverslips were placed onto these primary antibody solutions 
cell side down and kept at room temperature for two hours. After two 5-minute washes with 
PBS and two 5-minute washes with PBST (0.5% Tween in PBS), coverslips were treated 
with a secondary antibody for one hour and protected from light. Following dilutions were 
used: Alexa Fluor 555 goat anti-rabbit IgG (Invitrogen, Carlsbad, CA), 1:500; Alexa Fluor 555 
donkey anti-sheep IgG (Invitrogen, Carlsbad, CA), 1:250. Two PBS washes, three PBST 
washes, and a final PBS wash were done to remove unbound antibody. Slides were rinsed 
in Milli-Q® purified water to remove residual salts, then mounted with Vectashield Mounting 
Medium (Vector Laboratories, Burlingame, CA) with DAPI and visualized using a Zeiss LSM 
5 Pascal confocal microscope with a 100·objective lens (Carl Zeiss AG, Oberkochen, 
Germany). 
Protein modeling 
The location of the mutations in different functional domains was visualized using available 
NMR structures for the N-domain24, N-terminal Cu-binding unit domain25 and the A-domain26. 
The structures of the P-domain where modeled using the ESyPred3D Web Server 1.0 and 
the crystallographic structures of CopA ATP-binding domain as template (RCSB accession 
number 2b8e)27,28. 
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Results 
In vitro copper transport assay 
We first determined whether an ATP7B-dependent copper transport can be detected in 
ATP7B-containing microsomal vesicles from Sf9 cells used as a model for TGN vesicles. In 
the presence of ATP, the addition of 64Cu resulted in an accumulation of copper in ATP7B-
containing vesicles (Figure 2); whereas no transport was observed in vesicles prepared from 
cells infected with empty virus (mock) (Figure 2A). To verify that copper accumulation was 
due to an enzymatically-driven process, we repeated experiments at 4°C. No copper 
accumulation was observed at 4°C (Figure 2A). Orthovanadate (200 µM Na3VO4), a general 
inhibitor of P-type ATPases, significantly inhibited but did not fully eliminate copper uptake 
(Figure 2A). Consequently, to further verify that copper accumulation was due to transport 
and not simply binding of copper to ATP7B, we analyzed the D1027A mutant of ATP7B, in 
which catalysis is disrupted but copper binding is preserved. This mutant yielded no copper 
accumulation in vesicles (Figure 2B). 
The effect of mutations on copper transport 
To determine the effect of mutations on ATP7B transport function, we generated 25 WD-
associated variants and three predicted polymorphisms. Substitutions were made within 
different functional domains to better understand the structure-function relationships (Figure 
1B). The wt-ATP7B and mutants were expressed in the Sf9 cells under identical conditions. 
Western blot analysis illustrated that protein expression was easily detectable for all mutants 
(Supplementary Figure 1). In contrast, there was a marked variation in copper transport 
(Table 1, Figure 2C,D, Supplementary Figure 2). The majority of ATP7B mutants (16 out of 
total 25) had essentially no activity (less than 5% of wt) or a very low activity (5-10%); the 
H1069Q mutant (frequently found in Caucasian population) belonged to this latter category 
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(Figure 2C). Unexpectedly, a sizeable fraction (8 out of 25) of mutants showed partial 
transport activity (0.22-0.71 nmol/mg protein at 120 min). These mutants included A874V 
(frequently detected in Korean population29) and I857T. Most of the partially active mutants 
had slower transport rates and accumulated less copper than the wt-ATP7B, except the 
S406A variant that had a slower rate compared to the wt but with time yielded the same level 
of copper accumulation in vesicles (Figure 2C,D). Only one of the ATP7B mutants, M645R, 
displayed Cu-uptake (1.18 nmol/mg protein at 120 min) indistinguishable from wt-ATP7B 
(Figure 2C). The predicted non-disease variants (V456L and K832R) also showed reduced 
transport rates (Figure 2D). To further verify that these marked variations in activity were not 
simply due to differences in ATP7B expression levels, we selected several mutants that had 
similar transport activity, expressed them in parallel under identical conditions, and 
quantified ATP7B amounts by densitometry. Supplementary Figure 3 illustrates that a 
drastically different activity of these mutants is not due to difference in their expression 
levels. 
Effect of mutations on catalytic activity 
The loss of copper transport could be either due to disruption of copper transfer across 
membranes or due to the loss of ATP binding/hydrolysis. To better understand which of the 
steps is affected, we examined the ability of ATP7B to form a phosphorylated intermediate 
upon ATP binding (Figure 3, Table 1). In all A-domain mutants phosphorylation was 
markedly increased (Figure 3C). This result indicated that ATP-binding is unaltered, but the 
well-known function of the A-domain to facilitate dephosphorylation11 was inhibited. In 
contrast, ATP7B variants with mutations in the N-terminal domain (Figure 3A), 
transmembrane domain (Figure 3B), the P- or N-domains (Figure 3D, and E respectively) 
showed either normal or reduced phosphorylation. All three ATP7B gene variants not 
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associated with disease showed normal phosphorylation activity (Figure 3F). Thus, in our 
subset of mutants, disruption of ATP binding is not a major defect. 
Partial transport activity along with hyperphosphorylation for several mutants suggested that 
these mutants have altered conformation (or defects in the communication between 
functional protein domains necessary for optimal protein activity). This conclusion was 
supported by experiments on dephosphorylation. When hyperphosphorylated mutants were 
incubated with cold ATP, dephosphorylation was observed for all examined mutants (Figure 
4A,B). Thus, the hyperphosphorylated mutants are able to perform all the steps of the cycle 
and the transport defect in these mutants is associated with structural changes affecting 
rates of the individual step(s). 
Expression and localization of functional ATP7B mutants in mammalian cells 
The ability of several mutants to hydrolyze ATP and transport copper in vitro suggested that 
in cells their properties can further be altered exacerbating the phenotype. To test this 
hypothesis, three transport competent mutants (found in different domains: A-domain 
(A874V), N-domain (L1083F) and in the trans-membrane domain (R969Q)) were produced 
as GFP-tagged versions and their expression and localization were examined in mammalian 
cells. The R969Q variant showed fluorescent intensity similar to that of the wt-ATP7B and 
normal intracellular targeting, as illustrated by co-localization with the TGN marker TGN46 
(Figure 5). In contrast, L1083F and A874V showed significant abnormalities in their sub-
cellular localization and protein levels. When expressed at 37°C, L1083F and A874V 
displayed characteristic endoplasmic reticulum (ER) localization, which was confirmed by co-
staining with the ER marker Calnexin (Figure 5). Both mutants also showed weaker signal 
intensity compared to wt-ATP7B. Thus, despite the lack of gross misfolding (indicated by the 
ability to perform key functional reactions in vitro), the structural changes in A874V and 
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L1083F mutants were sufficient to produce apparent destabilization and ER retention. Thus, 
mislocalization is the major reason for the loss of copper delivery to the TGN by these 
mutants. 
Previous studies reported that the stability and localization of some ATP7B mutants (e.g. 
R778L and H1069Q) can be corrected by growing cells at 30°C17. Consequently, we tested 
whether the targeting of A874V and L1083F (which show copper transport activity after 
being expressed at 27oC in Sf9 cells (Table 1, Supplementary Figure 2B,D)) can be 
corrected by lowering temperature during expression. For A874V no improvement in either 
protein levels or targeting was seen in mammalian cells maintained at 28°C (attempts to 
stabilize this mutant by growing cells with increasing copper concentrations were also 
unsuccessful, data not shown). For the L1083F mutant, some TGN localization could be 
detected, but cold temperature alone was insufficient to induce TGN targeting 
(Supplementary Figure 4). 
Discussion 
ATP7B variants have a wide spectrum of properties. In this study we have investigated the 
effect of WD-causing mutations on the functional activity and intracellular functionality of 
ATP7B. Utilization of a heterologous expression system and membrane vesicles allowed us 
for the first time to directly evaluate the transport activity of a large set of clinically relevant 
mutants. Our results indicate that a significant diversity already exists at the molecular level, 
as the mutants display a markedly different stability, localization, catalytic, and transport 
activity. Therefore, detailed characterization of each WD-causing mutant may be necessary 
for better understanding of the genotype-phenotype correlations in WD. Although mutations 
located in the same domain may have similar properties (for example, we detected 
increased levels of phospho-intermediate in the A-domain mutants), the localization in a 
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certain domain alone is not predictive of the properties of a mutant. This conclusion can be 
illustrated by different transport characteristics of the P840L and I857T, both situated in the 
A-domain (Figure 6A). The more severe effect of P840L on protein function is likely due to a 
more disruptive nature of Pro>Leu substitution (replacing a small and kink-inducing Pro 
residue with a bulky and hydrophobic Ile) compared to replacement of Ile with a smaller Thr. 
The comparison of A874V with the recently characterized G875R variant further illustrates 
an extremely delicate and precise architecture of the ATP7B molecule30. The A874V 
mutation is located within the flexible loop of the A-domain (Figure 6A) and is not expected 
to markedly alter protein structure. This prediction is consistent with the actual functional 
properties of the mutant, i.e. its ability to transport copper using ATP hydrolysis. And yet, in 
cells the lack of precise folding prevents the A874V exit from the ER, thus disrupting copper 
delivery to the secretory pathway and likely causing WD phenotype. Similar ER retention of 
G875R (the mutation of a neighboring residue) can be corrected by increasing copper 
concentration in cells30, which facilitates ER exit and proper TGN targeting (and activity). In 
contrast, treatment with copper does not improve the A874V stability or localization. 
Altogether, our studies demonstrate the need for utilizing an arsenal of methods for 
understanding the phenotype of disease-causing mutation, since individual assays yields 
only partial and non-overlapping information about ATP7B properties. 
It is useful to compare the advantages and disadvantages of various assays and information 
that can be generated. Yeast complementation assay is an effective way to identify ATP7B 
mutants, which completely lost their transport activity from those that have some activity 
left12. However, it is difficult to draw more specific conclusions about properties of the WD 
mutants because it is unknown how much copper transport activity is necessary to allow 
yeast to grow. Overexpression of mutants with very low activity might be sufficient to allow 
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copper delivery to the TGN and growth. In addition, yeast cells grow at lower temperature 
(30oC), which may be sufficient to stabilize proteins that unfold and degrade at 37oC. For 
example, H1069Q, which has low copper transport activity and is unstable in mammalian 
cells13 complements yeast phenotype31 
Expression in insect cells may underestimate the effects of mutation on protein stability due 
to lower temperature necessary for growth of insect cells (27°C). However, it provides a 
marked advantage when detailed mechanistic understanding of functional consequences of 
mutations is desirable. We found that measurements of catalytic phosphorylation and 
dephosphorylation of ATP7B mutants expressed in Sf9 cells were the least predictive of the 
overall functional outcome of mutations as many mutants that showed no transport activity 
were still able to undergo catalytic phosphorylation. Since the phosphorylation assay is least 
sensitive, we suggest that the mutants that show no activity in this assay are most severely 
affected. Indeed, these mutants (G85V, L492S, G1266R, E1046K, and D1222V) show 
neither catalytic nor transport activity. The marked effect of the last three mutations on ATP 
hydrolysis is not surprising as they all affect conserved residues in the immediate vicinity to 
ATP (Figure 6A). In contrast, dramatic negative effects of G85V and L492S mutants were 
unexpected as both residues belong to the regulatory N-terminal domain, which is thought 
not to be critical for ATP binding and hydrolysis. We hypothesize that these mutants may 
mediate their effect indirectly through interaction with other functional domains. Because the 
N-domain interacts with the ATP-binding domain and these interactions affect protein 
activity32, abnormal inter-domain interaction due to mutation may decrease affinity for ATP 
and/or trap protein in conformation not suitable for ATP hydrolysis. 
The transport assay is the most direct way to evaluate ATP7B function. This assay identified 
several mutants that were transport competent, i.e. could be functional in a cell. Identification 
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of such mutants is particularly important, because they are promising candidates for possible 
corrective therapy. Such variants include M769V, I857T, A874V, all located in the A-domain, 
(Figure 6A, left). Unlike mutations in the P- and N-domains (Figure 6A middle, right), there 
residues are not involved in the formation of the substrate binding sites and their substitution 
is more likely to alter protein stability or targeting. As described above, characterization of 
one of this mutant A874V revealed limitations of the in vitro assays (and possibly all 
heterologous systems) in predicting the mutant phenotype in mammalian cells. In 
mammalian cells at either 28°C or 37°C, A874V has the ER localization and low expression 
pointing to significant instability of this mutant. Such instability was not detected in insect 
cells suggesting that mammalian cells have much more sensitive protein quality control. 
Combination of the in vitro and in vivo assays also discriminates between the effects of 
mutations on protein folding and function. Protein stability in cells is not indicative of function, 
because catalytically inactive mutants could be structurally stable, whereas partially active 
mutants may degrade rapidly, producing a “complete-loss of function” phenotype. Having 
information on both parameters could be particularly important for future attempts to correct 
the mutant phenotype by improving protein stability. For example, increasing stability of 
mutants such as the A874V mutant could be beneficial, because A874V has a significant 
transport activity. Recent studies using pharmacological folding chaperones 4-
phenylbutyrate and curcumin illustrate a possibility of correcting the stability/folding defects 
of several ATP7B mutants in cells17. In contrast, improving stability of other mutants (such as 
G85V or mutants located in the vicinity of the key functional sites, Figure 6A) can be without 
effect since these mutants lack catalytic and transport activity. Lastly, our studies revealed 
that the non-disease causing changes (V456L and K832R) may nevertheless decrease 
ATP7B activity. Thus presence of such variants, while by itself no causative, may have a 
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compound effect when found in combination with other mutations and put carriers at 
disadvantage. 
In conclusion, mutations in ATP7B have various effects altering protein expression levels, 
catalytic and transport activity, as well as intracellular localization (Figure 6B). Mutants with a 
partial preserved transport function may result in later onset of disease or have variable 
manifestation if their stability and localization is modulated by the metabolic state of cells. 
Detailed characterization of ATP7B mutants is likely to contribute to the analysis of 
genotype-phenotype correlations in WD. 
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Table 1 
Copper transport and phosphorylation activity of wild-type, mutant, and variant ATP7B 
(A-domain: Actuator domain; NTD: N-terminal Cu-binding domain; N-domain: 
nucleotide-binding domain; P-domain: phosphorylation domain; TMD, transmembrane 
domain; see Figure 1B). Copper uptake was considered impaired (no) (<5% of wt at 120 
min, 0-0.07 nmol/mg); low (5-10% of wt, 0.08-0.14 nmol/mg); partial (11-75% of wt, 
0.15-0.99 nmol/mg); normal (>75% of wt, >1.0 nmol/mg). The ability to form 
phosphorylated intermediate (catalytic phosphorylation) was considered normal (60-
140% of wt); inactive (<60% of wt); hyperphoshorylated (>140% of wt). Mutations 
highlighted in bold are predicted to be most severe (markedly affect copper transport or 
both functionalities), whereas mutations highlighted in italics are likely to be less severe 
or potentially correctable. 
 Protein domain 
Cu-uptake at 
120 min 
(nmol/mg 
protein); (SD) 
Transport
Phosphorylation 
activity (% of 
wt); (SD) 
Activity 
wt-ATP7B - 1.33 (0.18) normal 100.0 normal 
Artificial mutant of phosphorylation site: 
D1027A P-domain 0.04 (0.01) no 25.6 (8.4) inactive 
Human mutants: 
G85V NTD 0.11 (0.02) low 27.3 (25.3) inactive 
L492S NTD 0.11 (0.02) low 43.6 (16.5) inactive 
R616W NTD 0.14 (0.01) low 223.1 (28.2) hyperphosph. 
G626A NTD 0.28 (0.01) partial 86.3 (37.9) normal 
M645R NTD 1.18 (0.06) normal 167.3 (74.5) hyperphosph. 
G710S Loop 2-3 0.08 (0.01) low 69.1(24.6) normal 
P760L TMD 4 0.09 (0.07) low 152.1 (46.8) hyperphosph. 
D765N TMD 4 0.61 (0.02) partial 148.0 (97.9) hyperphosph. 
M769V TMD 4 0.65 (0.01) partial 203.3 (32.9) hyperphosph. 
P840L A-domain 0.08 (0.01) low 292.9 (83.7) hyperphosph. 
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I857T A-domain 0.65 (0.03) partial 202.4 (50.0) hyperphosph. 
A874V A-domain 0.71 (0.02) partial 162.1 (57.3) hyperphosph. 
R969Q Loop 5-6 0.37 (0.00) partial 291.4 (72.9) hyperphosph. 
P992L P-domain 0.23 (0.03) partial 129.0 (20.9) normal 
T1031S P-domain 0.09 (0.03) low 126.0 (57.9) normal 
P1052L P-domain 0.02 (0.00) no 90.7 (70.0) normal 
E1064K N-domain 0.03 (0.01) no 16.9 (11.0) inactive 
H1069Q N-domain 0.13 (0.01) low 51.4 (29.9) inactive 
L1083F N-domain 0.22 (0.02) partial 98.6 (25.1) normal 
G1213V P-domain 0.03 (0.00) no 119.8 (20.2) normal 
D1222V P-domain 0.11 (0.02) low 17.9 (6.0) inactive 
G1266R P-domain 0.08 (0.01) low 38.3 (35.3) inactive 
N1270S P-domain 0.02 (0.02) no 254.2 (126.9) hyperphosph. 
P1273L P-domain 0.18 (0.01) partial 245.6 (166.2) hyperphosph. 
S1362F-fs TMD 8 0.17 (0.01) partial 53.8 (13.2) inactive 
Human variants: 
S406A NTD 1.08 (0.01) normal 137.5 (45.1) normal 
V456L NTD 0.50 (0.02) partial 115.5 (58.2) normal 
K832R A-domain 0.92 (0.00) partial 130.0 (58.6) normal 
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Figure Legends 
 
Figure 1. (A) Catalytic cycle of ATP7B (the dotted frame highlights partial reactions, 
relevant for this study). (B) Transmembrane organization of ATP7B and representation 
of mutants and variants examined in this study. The six metal-binding sites in the N-
terminal Cu-binding unit domain (NTD) of ATP7B are indicated by letters CxxC. ATP is 
bound to the nucleotide binding domain (N) and phosphorylated during ATP hydrolysis. 
The site of ATP-hydrolysis is the invariant residue D1027 (D1027A mutant = bold, 
arrow). The gene variants S406A, V456L and K832R are highlighted in italic. The CPC 
motif located in the sixth transmembrane domain is thought to form the intramembrane 
copper-binding site(s). A denotes the actuator domain. 
 
Figure 2. (A) Copper transport by wt-ATP7B. Averages of ten independent experiments 
are shown. Copper uptake into vesicles was measured in nmol/mg protein over a time 
period of 240 min. Na3VO4 was added to the incubation solution to a final concentration 
of 200 µM (B) Mutation of the phosphorylation site of ATP7B (D1027A) abolishes Cu 
transport. (C) Copper transport by ATP7B mutants or (D) variants; Averages of three 
independent experiments are shown (mutants were selected to represent different 
functional domains; data for more mutants are shown in Table 1 and Supplementary 
Figure 2). 
 
Figure 3. Phosphorylation activity of ATP7B mutants (A-E) and variants (F): The protein 
gels show representative 32P autoradiograms of phosphorylated wt-ATP7B, variants and 
mutants. The phosphorylation activity (bar graphs) of variant and mutant ATP7B was 
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calculated in respect to wt-ATP7B activity (100%). Averages of 4-6 independent 
experiments are shown. 
 
Figure 4. ATP-dependend dephosphorylation of the A-domain mutants (A) and P-
domain mutants (B) of ATP7B at a copper concentration of 1 µM. ATP was added after 
[γ-32P] ATP phosphorylation to a final concentration of 1 mM and incubated for 10 min at 
room temperature before the reaction was stopped. The typical gels and the 
phosphorylation activities of mutant ATP7B calculated in respect to wt-ATP7B activity 
(100%) for 3 independent experiments are shown. 
 
Figure 5. Expression and localization of ATP7B mutants in mammalian cells. GFP-
tagged ATP7B variants were expressed in HEK 293 T RExTM cells. The expression 
pattern of wt- and mutant ATP7B is shown in the left column (green), organelle markers 
in the middle (red), and the superimposition of these images on the right (yellow). 
TGN46 is a TGN marker; Calnexin is marker for ER. 
 
Figure 6. (A) Location of the characterized mutations in the functional domains of 
ATP7B. The structure of the P-domain was software-modeled using crystallographic 
structure of CopA (2B8E) as a template. For mutations within the N-domain, available 
NMR data (2ARF) were used. The NMR-based model for the A-domain was kindly 
provided by Dr. Lucia Banci. (B) Summary of key properties of ATP7B (left panel) that 
are affected by various mutations examined in this study (right panel). 
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